HCA Healthcare, Inc. (HCA)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-09-29. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 11/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 4.33% of float, squeeze risk: MODERATE
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Can HCA Healthcare (HCA) Overcome Healthcare’s Margin Pressures?
- Can Shorter Hospital Stays Help HCA Handle More Patient Demand?
- Can HCA Sustain Earnings Growth Despite a Changing Service Mix?
- HCA Healthcare (HCA) Acquires a Healthcare College. Can Training Capacity Improve Staffing?
- HCA Healthcare Sees Solid Demand as Exchange Headwinds Pressure 2026 Outlook
- Alluvium Increases HCA Healthcare (HCA) Holdings After Its 17.5% Selloff
- HCA Healthcare Completes Acquisition of the College of Health Care Professions
- HCA Healthcare Delivers Consistent Message Around H2 Cadence Expectations, RBC Says
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for HCA Healthcare, Inc..
Full HCA Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.